How are AI and machine learning being used to treat Lymphoma

AI and Machine Learning in Lymphoma Treatment

This is a great question about an emerging area in cancer care. Let me explain how AI and machine learning are beginning to support lymphoma treatment, based on current medical evidence.

Current Applications in Lymphoma Care

1. Molecular Residual Disease (MRD) Detection

One of the most promising applications is detecting remaining cancer cells after treatment using advanced blood tests. According to recent developments included in NCCN Guidelines for B-Cell Lymphomas (December 2024), machine learning algorithms are now being used to analyze circulating tumor DNA (ctDNA)—fragments of cancer DNA floating in the bloodstream.

For example, the Foresight CLARITY Lymphoma test uses a technology called PhasED-Seq (Phased variant Enrichment and Detection Sequencing) that employs machine learning to:

• Detect cancer cells that remain after treatment with 90% sensitivity
• Identify relapse approximately 200 days (6-7 months) earlier than traditional PET/CT imaging
• Help guide whether additional treatment is needed before symptoms appear

This is validated for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and other B-cell lymphomas.

2. Treatment Planning and Biomarker Analysis

AI is helping oncologists interpret complex genetic and molecular information about lymphoma cells. According to NCCN Guidelines for Marginal Zone Lymphomas, mutation testing identifies specific genetic changes in cancer cells—such as deletions, amplifications, translocations, and point mutations. Machine learning algorithms help:

• Analyze these mutations quickly and accurately
• Match mutations to targeted therapies that work against them
• Predict which patients are likely to respond to specific treatments

3. Imaging Analysis

While NCCN Guidelines describe traditional imaging (CT, MRI, PET scans) as standard tools, AI is increasingly being used to:

• Analyze imaging more precisely to detect lymphoma deposits
• Measure tumor burden more accurately
• Track changes in tumors over time during treatment

Important Limitations and Current Status

These are emerging tools, not yet standard everywhere. Here's what you should know:

• MRD testing like CLARITY Lymphoma is currently available primarily through research trials and limited clinical use (expected broader clinical launch in 2026)
• Regulatory status: Many AI-powered tests are CLIA-certified laboratory tests but not yet FDA-approved
• Reimbursement: Insurance coverage is not yet established for many of these tests
• Clinical decision-making: Your oncologist still makes all treatment decisions—AI is a tool to support, not replace, medical judgment

Questions to Ask Your Oncology Team

If you're interested in how AI and advanced testing might apply to your care:

1. Are there any molecular residual disease (MRD) tests available for my type of lymphoma?
2. Are there clinical trials using AI-powered testing that I might be eligible for?
3. How do you currently use genetic/molecular testing to guide my treatment decisions?
4. What emerging technologies are you monitoring for my specific lymphoma type?
5. Are there any AI-based imaging or analysis tools being used in my treatment planning?

The Bottom Line

AI and machine learning are creating exciting opportunities to detect lymphoma recurrence earlier and personalize treatment decisions. However, these tools are still relatively new in clinical practice. Your healthcare team is best positioned to discuss which technologies are appropriate and available for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.